Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
| Autor: | Caroline Flament, Sophie Viaud, Mustapha Zoubir, Vincent Ribrag, Jean-Charles Soria, Nathalie Chaput, Patricia Pautier, Virginie Marty, Caroline Robert, A. Lecesne, Laurence Zitvogel, Philippe Vielh |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Cancer Research Cyclophosphamide medicine.medical_treatment Melanoma Experimental medicine.disease_cause T-Lymphocytes Regulatory Piperazines Autoimmunity Mice chemistry.chemical_compound Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Inducer Antineoplastic Agents Alkylating Aged business.industry Melanoma Cancer Cell Differentiation Immunotherapy Middle Aged medicine.disease Lymphocyte Subsets Nitrogen mustard Mice Inbred C57BL Pyrimidines Imatinib mesylate Oncology chemistry Benzamides Immunology Imatinib Mesylate Cancer research Interleukin-2 Th17 Cells Female business medicine.drug |
| Zdroj: | Cancer Research. 71:661-665 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4+ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients. Cancer Res; 71(3); 661–5. ©2010 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|